Proteotech And Tasly Pharmaceuticals Announce Alzheimer's Disease Drug Developme 5th October 2010 - Views: 1071 Tasly Pharmaceutical Co., Ltd. (Tianjin, China) and ProteoTech, Inc. (Kirkland, WA, USA) today announced an agreement to co-develop ProteoTech's novel small molecule therapeutic, Exebryl-1(R), for the treatment of mild-to-moderate Alzheimer's disease.